MOLNUPAC 200/MOLNUPAC 400 is indicated for treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education